Neuroblastoma is the most common extracranial, solid tumor in children. Despite intensive chemotherapy and bone marrow transplantation, the 5-year projected survival rate is 20% to 25%. In vitro studies have shown enhanced natural killer cell (NK) lysis of tumor cells after exposure of NK cells to interleukin-2 (IL-2). In vivo studies have demonstrated similar immunologic effects but have also revealed severe toxicities associated with the use of IL-2. IL-l2 is a newly described cytokine that has several properties, including the ability to act synergistically with IL-2 in generating lymphokine-activated killer cells (LAK) against known tumor targets. We investigated the role of IL-l2 in EUROBLASTOMA is the most common extracranial, solid tumor in children. Although considerable progress has been made in the treatment of stage IV neuroblastoma, this disease still carries a poor prognosis.' With conventional chemotherapy alone, approximately 8% of children with stage IV neuroblastoma survived after 2 years. With high-dose chemotherapy followed by bone marrow transplantation (BMT), about 40% of these children survive after 2 years. However, projected survival is between 20% and 2590 because of late relapse.2
or T-cell activating capacity led to the discovery of IL-12 or NK cell stimulatory factor (NKSF).'3"5 IL-12 is a recently described 70-kD heterodimeric cytokine comprised of a p35 and a p40 ~ubunit.'~-'' It was originally purified from B-lymphoblastoid cell lines NC-37I4-I6 and RPM1 8866.l3.l8 IL-12 has been shown to induce interferon-y and other cytokines, to enhance the cytotoxicity of both T and NK cells, to induce the proliferation of activated T and NK cells, and to create synergy with IL-2 in the generation of lymphokineactivated killer (LAK) cells against conventional NK tumor targets. '9-23 In light of these reports, we set the goal to determine if IL-12 might be of use against neuroblastoma and designed experiments to examine if peripheral blood mononuclear cells (PBMC) from normal, healthy donors and from children with neuroblastoma could be activated by IL-12 alone, or in combination with IL-2, to recognize and lyse neuroblastoma cell lines. Another goal was to identify if large granular lymphocytes (LGL) or T cells were responsible for this lytic activity. ity was associated with an important signaling adhesion molecule, CD 18, identified as the p chain of the CD 1 1 family of adhesion glycoproteins, and shown previously by us and others to be essential for the cytolytic p r o~e s s .~'~~
MATERIALS AND METHODS

Tumor cell lines.
Tumor cell lines were maintained by standard cell culture techniques and placed in RPMI-1640 medium (GIBCO Laboratories, Grand Island, NY) containing 10% heat-inactivated fetal calf serum (Hyclone, Logan, UT), 2 mmol/L L-glutamine, 10 U/mL penicillin, 100 IrglmL streptomycin, 5 mmol/L HEPES buffer (GIBCO), and 5 X IO-' mol/L 2-mercaptoethanol (Sigma, St Louis, MO). K562 cells, an erythroleukemia cell line, were maintained in suspension. NB100, NB212, and UCH-I cell lines are all adherent neuroblastoma cell lines and were a gift of Diana Worthington-White (University of Florida, Gainesville). The neuroblastoma cell lines were harvested by brief trypsinization with 0.25% trypsin and 0.04% EDTA in phosphate-bu&red saline (PBS).
Patient eligibility. Blood samples from three children with neuroblastoma were evaluated. No patient had received chemotherapy in the 2 weeks before evaluation. Informed consent was obtained from each family before removal of blood sample. Patients no. 1 and 2 were receiving multiagent chemotherapy courses. Patient no. from healthy donors at the Southwest Florida Blood Bank or I O mL of peripheral blood from patients was obtained. Samples were diluted 1.2 in PBS (M.A. Biologics, Walkersville, MD). The cells were layered over 14 mL of Ficoll-Paque (Pharmacia, Piscataway, NJ). After centrifugation at 400g for 20 minutes at room temperature, the interface band of PBMC was collected and washed twice with PBS. The collected PBMC were then suspended in RPMI-1640 medium (GIBCO) containing 5% heat-inactivated human AB serum (Biocell Laboratories, Carson, CA), 2 mmol/L L-glutamine, I O U/mL penicillin, 100 pg/mL streptomycin, 5 mmol/L HEPES buffer (GIBCO), and 5 X IO-' mol/L 2-mercaptoethanol (Sigma). Plastics were purchased from Costar (Cambridge, MA).
NK t~e N and T-cell isolation. Fresh buffy coats were obtained as described above and PBMC were further separated using plastic adherence for removal of monocytes followed by further removal of adherent cells and B lymphocytes by incubation on nylon wool columns for 30 minutes at 37°C. The cells passing through the columns were then placed on a six-step discontinuous density gradient with a range from 40% to 52.5% Per~oll.'~ After centrifugation at 550g for 30 minutes at room temperature the bands of lymphocytes were collected. LGL, obtained from Percoll fractions 2 and 3, were treated with anti-CD5 antibodies (anti-Leu-l; Becton Dickinson, San Jose, CA) and T cells, from fractions 4 through 7, were incubated with anti-CD16 antibodies (anti-Leu-l I b Becton Dickinson) for 40 minutes. The cells were then incubated with Immunobeads coated with goat antimouse IgG (Advanced Magnetics. Cambridge, MA). The labeled cells were removed by exposure to a strong magnetic field. Purified LGL and T cells were then counted and diluted to the appropriate concentration in media with 5% AB serum.
Cytotoxic assay. Cytotoxic activity was evaluated using chromium (5'Cr) release assays. Ninety-six-well, U-bottomed microwell plates were prepared with 100 pL, triplicate serial dilutions of PBMC in effector celktarget cell concentrations of 100:1, 50:1,25: I , and 12.5: I . Recombinant IL-2 (Hoffman-LaRoche, Nutley, NJ) (specific activity 2 X IO7 U/mg) and IL-12 (Genetics Institute, Cambridge, MA) (specific activity 8.5 X IO7 U/mg) were added to PBMC in concentrations ranging from 1 U/mL to 100 U/mL. The cells were then incubated at 37°C in 5% CO2 for 18 hours. Target tumor cells were counted and washed before 100 pCi of sodium "Crchromium (Amersham, Arlington Heights, IL) was added to 2 X IO6 cells and incubated at 37°C for I hour. The cells were washed twice with PBS and diluted to a concentration of 5 X 104/mL, then 100 pL of target cells was added to each well of the 96-well plates. After the cells were incubated at 37'C for 5 hours, 100 pL of supernatant was collected, and the radioactive content was measured by gamma scintillation counting. 
RESULTS
Preliminary data (not shown) indicated that the optimal time for activation of cytotoxic activity against tumor target cells was 18 hours. Initial experiments were designed to examine the ability of IL-12, alone and in combination with IL-2, to induce lytic function against NB100, an NK-resistant neuroblastoma cell line. Figure 1 illustrates the data from a representative experiment evaluating lytic activity against NB 100. As shown by the media control, PBMC are unable to lyse NB 100 tumor cells. Exposure of PBMC to IL-12 alone ( IO U/mL) did not increase the cytotoxicity of the PBMC significantly. IL-2 (100 U/mL) activated the PBMC more than IL-12 alone. However, the combination of IL-2 and IL-I2 achieved the greatest lysis of target cells ( P I .05), and activated PBMC to lyse the otherwise resistant NBIOO tumor cell line. LU for this experiment were calculated as described in Materials and Methods. Further data will be presented as LU for clarity.
To fully evaluate the responses of PBMC to IL-2 and IL-12, several doses of cytokines were tested to evaluate the dose response (Fig 2) . Again, IL-2 alone activated PBMCs against both NB100 and K562 in a dose-dependent fashion. When PBMC were incubated with IL-2 at a dose of IO U/ mL, LU achieved when tested against NB 100 were 44.4, and when tested against K562 LU were 358.4. When PBMC were incubated with a higher dose of IL-2 (100 U/mL), LU were higher (153.5 for NBIOO and 455.8 for K562). IL-12 activation of PBMC was also dose dependent and LU for PBMC incubated with IL-12 at doses of 1 U/mL and IO U/ mL when tested against NBIOO were 19.6 and 54.4, respectively, and against K562 were 194.8 and 363.6, respectively. However, in all cases the response to IL-12 alone was less than the response to either IL-2 (100 U/mL) or IL-12 plus IL-2. The combination of IL-12 ( I O U/mL) and IL-2 (100 U/mL) most effectively activated the cytolytic capacity of PBMC. LU of PBMC activated by the combination of these two cytokines tested against NB I O 0 were 242.1 and against
UCH-I
K562 were 455.8. As illustrated by these data and as expected, the tumor cell line K562 was more sensitive to lysis by activated PBMC than was the NBIOO tumor cell line.
In an effort to show that these findings were not limited to the NB 100 cell line, NB 100 cells and two other neuroblastoma cell lines, NB2 12 and UCH-I , were tested. Similar patterns of activation were seen with NB2 12 and UCH-I (Fig 3) . However, NB100 was the most sensitive cell line. PBMC activated by both IL-2 and IL-12 were the only cells able to lyse UCH-I , an otherwise NK-cell-resistant tumor cell line.
The next step was to test PBMC from children with neuroblastoma to see if these cells could be activated by IL-2 and IL-12. None of the patients had been treated with chemotherapy in the 2 weeks before evaluation. PBMC from all three of the children were activated by IL-2 and IL-12 and were able to kill neuroblastoma cells (Fig 4) . As seen with the healthy donor cells, PBMC from these children were activated to the greatest extent by the Combination of IL-2 and IL-12.
To identify the effector cells responsible for the lysis of these tumor cells, PBMC were further separated into LGL and T cells as described in Materials and Methods. When these two populations of cells were further purified by removal of T cells from LGL using anti-CD5 antibodies and removal of LGL from T cells using anti-CD16 antibodies, and tested against NBIOO cells, the LGL were responsible for the lytic activity (P I .05) (Fig 5) .
Finally, in light of previous findings showing the critical role of the CD 18 signaling adhesion molecule in IL-2-mediated LAK lysis, we questioned the role of CD 18 in the IL-12-dependent mechanism of lysis. Addition of anti-CD I8 antibodies, RH 1-38 and MC-44, clearly suppressed lysis of target cells (Fig 6) . IgG 1 and IgG2a controls did not interfere with PBMC-mediated lysis of NBl00. PBMC untreated with antibody achieved similar lysis of NBIOO cells as seen in previous experiments. By comparison, after incubation with IL-2 and IL-12 and testing against NB100, PBMC incubated with RHI-28 and MC-44 both had LU of 510 whereas those incubated with media, IgGI, and IgG2a achieved LU of76.2,99.5, and 77.8, respectively. Group (POG) phase I trial of IL-2 treatment of 7 children with advanced malignancies (5 children with ALL, 1 with neuroblastoma, and 1 with rhabdomyosarcoma) reported an increase in the in vitro NK cell cytotoxicity in 5 of the 7 patients treated. 6 The investigators noted that patients with the lowest initial NK cytotoxicity had the most dramatic increase in function. Negrier et all reported a phase I1 trial of IL-2 and LAK cell reinfusion in 15 children with neuroblastoma. Twelve children were in relapse after chemotherapy and autologous BMT and three had primary refractory disease despite conventional chemotherapy. Mean lytic function of NK cells, when tested against K562, Daudi, and SKNFI cell lines, increased after treatment with IL-2. Clinical toxicity seen in this trial was severe and included two toxic deaths. As with the POG phase I trial, no durable remissions were seen in the treated population. Alvarado et als showed an increase in the NK cell cytotoxicity of PBMC from children with neuroblastoma after 18-hour incubation of these cells with rIL-2 (50 U/mL) and testing against neuroblastoma cell lines CHP-126 and SKNSH. Favrot et a12 conducted a phase I1 trial of continuous infusion IL-2. The study consisted of two parts. In the first part of the trial, nine children with neuroblastoma in relapse after autologous BMT or with primary refractory disease received continuous infusion IL-2 and LAK cell reinfusion. Objective effects were seen in two of the nine patients. One had brief but dramatic decrease in the catecholamine and dopamine secretion and another had transient regression of subcutaneous cranial lesions. All nine children had progressive disease. The second part of the trial evaluated the use of IL-2 alone in two children who had persistent active disease 60 to 120 days after high-dose chemotherapy and BMT (one autologous and one allogeneic). One of these children experienced complete remission (8 months) after the second course of IL-2. The other child had recrudescence ofgraft-versus-host disease requiring interruption of IL-2 infusion. The patient subsequently developed progressive disease. NK and LAK cell function in these patients increased after IL-2 administration. Truitt et als conducted a phase I trial of 14 children with malignancy, six of whom had stage IV neuroblastoma. Again, they found the in vitro NK cell cytotoxicity to be increased in all children who received recombinant IL-2.
Because of the synergy seen with IL-2 and IL-12 in the generation of LAK cells, researchers have examined the role of IL-12 in NK cell activation. Soiffer et alZS evaluated PBMC from 12 patients with metastatic cancer and 13 patients who were within 2 months of allogeneic BMT. These researchers found IL-12 to enhance the cytotoxicity of PBMC and found the combination of IL-2 and IL-12 to be as effective or more effective than IL-2 alone when tested against K562, a known NK-sensitive erythroleukemia cell line.
Recently reported in vitro experience with IL-12 and prior in vitro and in vivo data on IL-2 treatment of neuroblastoma prompted us to evaluate the role of IL-12 in activation of NK cells against neuroblastoma. Neuroblastoma cell lines are NK resistant but the addition of IL-2, IL-12, or the combination activates NK cells and increases target cell lysis. Interestingly, the combination of both IL-2 and IL-12 does this most effectively. The data seen with normal, healthy donors were reproducible with PBMC from children with neuroblastoma. Interestingly, both the PBMC from patients undergoing multiagent chemotherapy and the PBMC from the patient who had undergone BMT were activated by IL-12. This shows that intensive chemotherapy does not blunt the response to these cytokines. The fact that LGL were depleted of T cells using anti-CD5 antibodies and T cells were depleted of LGL using anti-CD1 6 antibodies. After incubation with various doses of cytokines as shown in the legend, the cells were tested against NB100 in a 5-hour ''chromium release assay.
PBMC from children with neuroblastoma can be activated by IL-2 and IL-12 to kill neuroblastoma cells in a similar fashion to the PBMC from healthy donors suggests a potential therapeutic role for IL-12 in the treatment of neuroblastoma. That PBMC from children receiving multiagent chemotherapy are also activated by these cytokines indicates immunotherapy may possibly be used in concert with chemotherapy. Clinical trials have shown the severe toxicities associated with IL-2 treatment in the clinical setting. Because the concentration of IL-12 ( 1 to IO U/mL) needed to activate NK cells is lower than IL-2 (100 U/mL), and because the combination of the two affords some synergy, the possibility of using lower doses of IL-2 exists. IL-2 ( l 00 U/mL) and IL-l2 (1 0 U/mL) at 37'C for 1 8 hours, the cells were exposed to media, RH1-38 (1 mg/mL), MC-44 (1 mg/mL), lgGl (0.5 mg/mL), and IgG2a (1 mg/mL) antibodies for 5 minutes, and then a 5-hour "chromium release assay was performed using NB1 00 cells as the tumor target cells as described in Materials and
Methods.
We further sought to illuminate the question ofwhich cell was acting as the effector cell for NB 100 target cell lysis with IL-12 activation. Comparison of purified LGL-and T-cellmediated lysis implicates the LGL as the effector cell in NB100 target cell lysis. In CD18, a signaling adhesion molecule, has been shown to be critical in NK and cytotoxic T cell (CTL) lysis of target It has been shown that the functional display of CD1 8 on the effector cell but not on the target cell is necessary for NK-and CTL-mediated lysis of target cells.*' Our results indicate that the CD18 molecule is also essential in IL-12-activated NK cell lysis of target cells.
Further investigation of IL-12, its effects on NK cell function, and its potential role in the treatment of neuroblastoma is warranted.
